# US 2025/0205339 A1 · Formulation having improved absorbability of low-soluble and/or low-membrane-permeable drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205339 A1
- Document ID: US20250205339A1
- Status: Published application
- Kind: A1
- Application number: 18/852,301
- Filed: 2023-03-31
- Published: 2025-06-26
- Earliest claimed: 2022-03-31
- Assignees: Medrx Co., Ltd.
- Applicants: MEDRx Co., Ltd.
- Inventors: Takashi NAKAE; Yasushi MIWA; Hidetoshi HAMAMOTO; Noboru TATSUMI; Yutaka YAMAGATA
- Web page: https://patentgrep.com/patent/US20250205339A1

## CPC

- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a pharmaceutical composition comprising a drug with low solubility and/or low permeability and an ionic liquid, wherein the ionic liquid is an anion ingredient and a cation ingredient, the anion ingredient is oleic acid or isostearic acid, and the cation ingredient is selected from a cationic lipid as well as a transmucosal absorption enhancer or a gastrointestinal absorption enhancer comprising an ionic liquid, wherein the ionic liquid is an anion ingredient and a cation ingredient, the anion ingredient is oleic acid or isostearic acid, and the cation ingredient is selected from a cationic lipid.

## Claims

### Claim 1

A pharmaceutical composition comprising a drug with low solubility and/or low permeability and an ionic liquid, wherein the ionic liquid comprises an anion ingredient and a cation ingredient, the anion ingredient is oleic acid or isostearic acid, and the cation ingredient is selected from a cationic lipid.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the cationic lipid is DODAP, DODMA or DOTMA.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the anion ingredient is oleic acid and the cation ingredient is DODAP or DODMA.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the drug with low solubility and/or low permeability is PROTAC.

### Claim 5 (depends on 1)

An oral preparation comprising the pharmaceutical composition according to claim 1.

### Claim 6

A transmucosal absorption enhancer comprising an ionic liquid, wherein the ionic liquid comprises an anion ingredient and a cation ingredient, the anion ingredient is oleic acid or isostearic acid, and the cation ingredient is selected from a cationic lipid, provided that a drug is not comprised.

### Claim 7 (depends on 6)

A preparation comprising a drug with low solubility and/or low permeability and the transmucosal absorption enhancer according to claim 6.

### Claim 8

A gastrointestinal absorption enhancer comprising an ionic liquid, wherein the ionic liquid comprises an anion ingredient and a cation ingredient, the anion ingredient is oleic acid or isostearic acid, and the cation ingredient is selected from a cationic lipid, provided that a drug is not comprised.

### Claim 9 (depends on 8)

The gastrointestinal absorption enhancer according to claim 8, wherein the cationic lipid is DODAP, DODMA or DOTMA.

### Claim 10 (depends on 8)

The gastrointestinal absorption enhancer according to claim 8, wherein the anion ingredient is oleic acid and the cation ingredient is DODAP or DODMA.

### Claim 11 (depends on 8)

An oral preparation comprising a drug with low solubility and/or low permeability and the gastrointestinal absorption enhancer according to claim 8.

### Claim 12 (depends on 11)

The oral preparation according to claim 11, wherein the drug with low solubility and/or low permeability is PROTAC.
